ctrl K

Price Alert

KalVista Pharmaceuticals ... (KALV)

NASDAQ: KALV · Real-Time Price · USD

12.89

-0.06 (-0.46%)

At close: Aug 15, 2025, 3:46 PM

KalVista Pharmaceuticals Income Statement

Financials in USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Revenue	n/a	n/a	n/a	n/a	12.69M
Cost of Revenue	n/a	86.17M	802K	743K	651K
Gross Profit	n/a	-86.17M	-802K	-743K	12.04M
Operating Income	-188M	-140.44M	-110.87M	-96.61M	-57.92M
Interest Income	6.43M	n/a	2.23M	1.09M	903K
Pretax Income	-180.05M	-135.1M	-92.91M	-82.34M	-46.24M
Net Income	-183.44M	-126.64M	-74.85M	-68.51M	-44.49M
Selling & General & Admin	116.29M	54.28M	30.59M	26.45M	16.64M
Research & Development	71.71M	86.17M	80.28M	70.17M	41.29M
Other Expenses	n/a	-86.17M	n/a	n/a	9.93M
Operating Expenses	188M	54.28M	110.87M	96.61M	57.92M
Interest Expense	5.79M	n/a	n/a	1.09M	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	188M	140.44M	110.87M	96.61M	57.92M
Income Tax Expense	3.39M	-8.45M	-18.05M	-13.83M	-1.75M
Shares Outstanding (Basic)	49.65M	36.79M	27.89M	24.47M	19.09M
Shares Outstanding (Diluted)	49.65M	36.79M	27.89M	24.47M	19.09M
EPS (Basic)	-3.69	-3.44	-2.68	-2.8	-2.33
EPS (Diluted)	-3.69	-3.44	-2.68	-2.8	-2.33
EBITDA	-173.33M	-134.28M	-92.11M	-81.6M	-45.59M
EBIT	-174.27M	-135.1M	-110.87M	-96.61M	-57.92M
Depreciation & Amortization	941K	816K	802K	743K	651K